Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 3Glioma 2Diffuse Intrinsic Pontine Glioma 2Astrocytoma 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1Medulloblastoma 1Liver Cirrhosis 1Gliosarcoma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Stem Neoplasms 1Brain Neoplasms 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 125Nivolumab 84pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 42Leucovorin 40tremelimumab 37Radiofrequency Ablation 37camrelizumab 36Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28Hepatectomy 26Gemcitabine 26Cyclophosphamide 26cabozantinib 25Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × Mebendazole × Clear all
NCT04443049 2021-10-05

To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.

Institute of Liver and Biliary Sciences, India

Phase NA Unknown
170 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡